Real Chemistry Announces Board of Directors and CEO Advisory Board Appointments

Oracle Leader Bob Weiler Joins Board of Directors; Biopharma Market Access and Commercial Expert Dr. Amy Grogg Joins CEO Advisory Board from AmerisourceBergen

SAN FRANCISCO--(BUSINESS WIRE)-- Real Chemistry, a global health innovation company committed to making the world a healthier place for all, announced today that Bob Weiler, a seasoned technology executive, and Dr. Amy Grogg, a distinguished market access expert, will join the company’s Board of Directors and CEO Advisory Board, respectively. These appointments will support the company’s growth in these two priority areas as it continues to help customers stay ahead of the increasing consumerization, personalization and digitization happening across the healthcare ecosystem.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005233/en/

Dr. Amy Grogg

Weiler joins Real Chemistry’s Board of Directors with more than 40 years of leadership experience in the technology industry. He most recently served as Executive Vice President, Global Business Units, at Oracle. Grogg joins the company’s CEO Advisory Board with more than 25 years of healthcare services and distribution experience. She most recently served as Senior Vice President, Strategy and Commercialization, at AmerisourceBergen.

During his time at Oracle, Weiler oversaw Development Sales Marketing and Support for all vertical applications, including telecommunications, health science and hospitality. He also led the charge for integrating more than 30 acquired companies. Prior to his time at Oracle, Weiler led numerous other organizations, including Phase Forward, Giga Information Group and Eastman Software (formerly Wang Software).

“Real Chemistry is rapidly becoming a formidable developer of health technology products that will revolutionize the healthcare ecosystem, which is already evolving at an accelerated pace in part due to the COVID-19 pandemic. Providers and patients are using data and digital solutions in new ways in the search for critical information, and Real Chemistry is working to provide customers with the ability to meet them where they are,” said Weiler. “Helping companies like Real Chemistry use technology to improve the healthcare experience has been a lifelong mission of mine, which is why I’m very much looking forward to serving on the company’s Board of Directors.”

Grogg’s leadership helped position AmerisourceBergen as the preferred commercialization partner for biopharmaceutical and pharmaceutical manufacturers, and she held operational responsibility for many companies within its network, including Xcenda, Lash Group and Innomar Strategies. Before joining AmerisourceBergen, Grogg spent more than a decade in the pharmaceutical industry, primarily at Johnson & Johnson, where she led teams driving health economic, quality of life and patient-reported outcomes research studies for all of the company’s marketed products in the United States.

“In my own career shaping the commercialization journey for many pharmaceutical companies, I’ve never come across a company working as quickly – and smartly – as Real Chemistry,” said Grogg. “The company’s ability to provide data-driven counsel coupled with its expanding list of offerings is impressive, and I’m looking forward to playing a role in helping shape what’s next for the team and its customers.”

About Real Chemistry
Real Chemistry is a global health innovation company with an alchemic mix of 1,800 people and hundreds of clients and partners working from bench to bedside, making the world a healthier place. Purpose-built by Jim Weiss to address modern healthcare challenges, Real Chemistry is the culmination of 20 years of intentional, fiercely independent, sustained growth. With offices across the United States and Europe, Real Chemistry believes that the way to real, transformative change is through the uncommon combination of talents, disciplines and technologies.

Real Chemistry’s proprietary technology products include Swoop, IPM.ai and the Symplur Suite of social listening, analytics and engagement tools, all housed within Real Chemistry Health Technologies. Tools focused on clinical trial engagement live within Hū, and expert service brands include W2O (integrated communications), 21GRAMS (advertising and medical), Discern (value-based care consulting), and starpower (influencer and entertainment marketing). Integrated intelligence, media and marketing are all within Real Chemistry’s Integrated Marketing and Intelligence Services (IMIS).

For more information, please visit www.realchemistry.com and connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005233/en/